In a randomized, double-blind, crossover study conducted by Boschmann et al. [19], twenty patients with T2DM and a body mass index between 28 and 40 kg/m2 underwent a 7-day treatment with the selective DPP-4 inhibitor vildagliptin or placebo. Here, DPP4 is linked to type 2 diabetes mellitus.